200 related articles for article (PubMed ID: 25468570)
21. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes.
Takahashi H; Feuerhake F; Kutok JL; Monti S; Dal Cin P; Neuberg D; Aster JC; Shipp MA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3265-71. PubMed ID: 16740746
[TBL] [Abstract][Full Text] [Related]
22. Large B-cell lymphoma with Hodgkin's features.
García JF; Mollejo M; Fraga M; Forteza J; Muniesa JA; Pérez-Guillermo M; Pérez-Seoane C; Rivera T; Ortega P; Piris MA
Histopathology; 2005 Jul; 47(1):101-10. PubMed ID: 15982329
[TBL] [Abstract][Full Text] [Related]
23. BCL2 mutation spectrum in B-cell non-Hodgkin lymphomas and patterns associated with evolution of follicular lymphoma.
Burkhard R; Bhagat G; Cogliatti SB; Rossi D; Gaidano G; Pasqualucci L; Novak U
Hematol Oncol; 2015 Mar; 33(1):23-30. PubMed ID: 24496723
[TBL] [Abstract][Full Text] [Related]
24. AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-κB activation.
Tsai HJ; Shih NY; Kuo SH; Cheng AL; Lin HY; Chen TY; Chang KC; Lin SF; Chang JS; Chen LT
Leuk Lymphoma; 2015; 56(9):2674-82. PubMed ID: 25535814
[TBL] [Abstract][Full Text] [Related]
25. The endless complexity of lymphocyte differentiation and lymphomagenesis: IRF-4 downregulates BCL6 expression.
Lossos IS
Cancer Cell; 2007 Sep; 12(3):189-91. PubMed ID: 17785200
[TBL] [Abstract][Full Text] [Related]
26. Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.
Bohers E; Mareschal S; Bertrand P; Viailly PJ; Dubois S; Maingonnat C; Ruminy P; Tilly H; Jardin F
Leuk Lymphoma; 2015 May; 56(5):1213-22. PubMed ID: 25130477
[TBL] [Abstract][Full Text] [Related]
27. Elevated Choline Kinase α-Mediated Choline Metabolism Supports the Prolonged Survival of TRAF3-Deficient B Lymphocytes.
Gokhale S; Lu W; Zhu S; Liu Y; Hart RP; Rabinowitz JD; Xie P
J Immunol; 2020 Jan; 204(2):459-471. PubMed ID: 31826940
[TBL] [Abstract][Full Text] [Related]
28. Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.
Morin RD; Assouline S; Alcaide M; Mohajeri A; Johnston RL; Chong L; Grewal J; Yu S; Fornika D; Bushell K; Nielsen TH; Petrogiannis-Haliotis T; Crump M; Tosikyan A; Grande BM; MacDonald D; Rousseau C; Bayat M; Sesques P; Froment R; Albuquerque M; Monczak Y; Oros KK; Greenwood C; Riazalhosseini Y; Arseneault M; Camlioglu E; Constantin A; Pan-Hammarstrom Q; Peng R; Mann KK; Johnson NA
Clin Cancer Res; 2016 May; 22(9):2290-300. PubMed ID: 26647218
[TBL] [Abstract][Full Text] [Related]
29. Signaling mechanisms of bortezomib in TRAF3-deficient mouse B lymphoma and human multiple myeloma cells.
Edwards SK; Han Y; Liu Y; Kreider BZ; Liu Y; Grewal S; Desai A; Baron J; Moore CR; Luo C; Xie P
Leuk Res; 2016 Feb; 41():85-95. PubMed ID: 26740054
[TBL] [Abstract][Full Text] [Related]
30. Identification and characterization of receptor-interacting protein 2 as a TNFR-associated factor 3 binding partner.
Cai X; Du J; Liu Y; Xia W; Liu J; Zou M; Wang Y; Wang M; Su H; Xu D
Gene; 2013 Apr; 517(2):205-11. PubMed ID: 23333941
[TBL] [Abstract][Full Text] [Related]
31. Noncanonical NF-κB activation by the oncoprotein Tio occurs through a nonconserved TRAF3-binding motif.
de Jong SJ; Albrecht JC; Giehler F; Kieser A; Sticht H; Biesinger B
Sci Signal; 2013 Apr; 6(272):ra27. PubMed ID: 23612708
[TBL] [Abstract][Full Text] [Related]
32. Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.
Bognar MK; Vincendeau M; Erdmann T; Seeholzer T; Grau M; Linnemann JR; Ruland J; Scheel CH; Lenz P; Ott G; Lenz G; Hauck SM; Krappmann D
Oncogene; 2016 Aug; 35(32):4269-81. PubMed ID: 26776161
[TBL] [Abstract][Full Text] [Related]
33. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.
Gebauer N; Hardel TT; Gebauer J; Bernard V; Merz H; Feller AC; Rades D; Biersack H; Lehnert H; Thorns C
Anticancer Res; 2014 Oct; 34(10):5503-7. PubMed ID: 25275047
[TBL] [Abstract][Full Text] [Related]
34. miR-181a negatively regulates NF-κB signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis.
Kozloski GA; Jiang X; Bhatt S; Ruiz J; Vega F; Shaknovich R; Melnick A; Lossos IS
Blood; 2016 Jun; 127(23):2856-66. PubMed ID: 26941399
[TBL] [Abstract][Full Text] [Related]
35. [The action mechanisms of unclassical NF-kappaB activity and TRAF3 expression in Hodgkin's lymphoma cells].
Guo F; Wang WJ; Sun AN; Zhou P; Chen ZX
Zhonghua Xue Ye Xue Za Zhi; 2009 Oct; 30(10):678-82. PubMed ID: 19954665
[TBL] [Abstract][Full Text] [Related]
36. New developments in extracutaneous lymphomas.
Chott A; Raderer M
Semin Cutan Med Surg; 2000 Jun; 19(2):149-56. PubMed ID: 10892718
[TBL] [Abstract][Full Text] [Related]
37. TRAF3 deficiency promotes metabolic reprogramming in B cells.
Mambetsariev N; Lin WW; Wallis AM; Stunz LL; Bishop GA
Sci Rep; 2016 Oct; 6():35349. PubMed ID: 27752131
[TBL] [Abstract][Full Text] [Related]
38. First reported case of splenic diffuse red pulp small B-cell lymphoma with novel mutations in CXCR4 and TRAF3 genes.
Zheng S; Lin L; Jin J; Liu F; Wei J; Feng Y; Zhang Y; Luo H; Qin J; Feng W
Int J Hematol; 2023 Sep; 118(3):394-399. PubMed ID: 36935465
[TBL] [Abstract][Full Text] [Related]
39. Constitutive activation of alternative nuclear factor kappa B pathway in canine diffuse large B-cell lymphoma contributes to tumor cell survival and is a target of new adjuvant therapies.
Seelig DM; Ito D; Forster CL; Yoon UA; Breen M; Burns LJ; Bachanova V; Lindblad-Toh K; O'Brien TD; Schmechel SC; Rizzardi AE; Modiano JF; Linden MA
Leuk Lymphoma; 2017 Jul; 58(7):1702-1710. PubMed ID: 27931134
[TBL] [Abstract][Full Text] [Related]
40. Role of nuclear factor-κB regulators TNFAIP3 and CARD11 in Middle Eastern diffuse large B-cell lymphoma.
Bu R; Bavi P; Abubaker J; Jehan Z; Al-Haqawi W; Ajarim D; Al-Dayel F; Uddin S; Al-Kuraya KS
Leuk Lymphoma; 2012 Oct; 53(10):1971-7. PubMed ID: 22397314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
